Is widespread screening for hepatitis C justified?

@article{Koretz2015IsWS,
  title={Is widespread screening for hepatitis C justified?},
  author={Ronald L Koretz and Kenneth Weicong Lin and John P. A. Ioannidis and Jeanne Lenzer},
  journal={BMJ : British Medical Journal},
  year={2015},
  volume={350}
}
Several organisations have recommended greatly expanded screening for hepatitis C infection. Ronald Koretz and colleagues are concerned that no study has tested whether this will lead to net clinical benefit or harm in screened populations 
Screening and treatment for hepatitis C: a balanced perspective
TLDR
A contrasting view based on four key points is offered on a randomised trial of hepatitis C screening on the basis of a selective literature review. Expand
Should Family Physicians Routinely Screen Patients for Hepatitis C? No: One-time Screening Still Has Too Many Unanswered Questions.
  • K. Lin
  • Medicine
  • American family physician
  • 2016
Given current scientific uncertainties, limited resources, and evolving guidelines, a reasonable middle ground would be to focus HCV testing and therapy on patients who are most likely to haveExpand
Early diagnosis and treatment: the goal of hepatitis C screening
TLDR
The need for robust evidence for hepatitis C screening is highlighted, but a few points warrant a more balanced discussion, and the US birth cohort screening programme should be considered. Expand
USPSTF recommends screening adults 18 to 79 years for hepatitis C virus infection (moderate certainty)
  • R. Koretz
  • Medicine
  • Annals of Internal Medicine
  • 2020
TLDR
Screening for hepatitis C virus infection in adolescents and adults and US Preventive Services Task Force Recommendation Statement, 2020;323:970-5. Expand
Efficacy of Direct-Acting Antivirals Compared with Older Agents for Hepatitis C.
Although they help patients achieve sustained viralogic response, expensive direct-acting antivirals have yet to show that they can succeed in meeting top-priority treatment goals.
NICE’s recommendation on sofosbuvir for hepatitis C
Koretz and colleagues point out that new hepatitis C drugs need to be evaluated by long term follow-up of clinical outcomes and not just surrogate markers.1 However, the National Institute of HealthExpand
Hepatitis C screening of men who have sex with men
Koretz and colleagues failed to highlight hepatitis C (HCV) as an emerging sexually transmitted infection in men who have sex with men (MSM), and the public health implications.1 The past decade hasExpand
Response from Hepatitis C Trust, BASL, BIA, BVHG, BSG, and BHIVA to article asking whether widespread screening for hepatitis C is justified
TLDR
The authors argue that because a community study showed an increase in liver and non-liver mortality most infected people will not die from HCV, and screening should be delayed. Expand
Hepatitis C in a prison in the North East of England: what is the economic impact of the universal offer of testing and emergent medications?
TLDR
Testing for hepatitis C virus infections in people who inject drugs and in prescribed places of detention for PPDs shows positive results for sofosbuvir and ledipasvir-SFOV, respectively. Expand
Centers for Disease Control and Prevention: protecting the private good?
  • J. Lenzer
  • Business, Medicine
  • BMJ : British Medical Journal
  • 2015
After revelations that the CDC is receiving some funding from industry, Jeanne Lenzer investigates how it might have affected the organisation’s decisions
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 84 REFERENCES
Curing chronic hepatitis C--the arc of a medical triumph.
The development of direct-acting antiviral agents has revolutionized the treatment of hepatitis C by offering genuine prospects for a comprehensive cure of a chronic viral infection. This success canExpand
Natural history of hepatitis C in thalassemia major: a long‐term prospective study
TLDR
The natural history of post‐transfusional hepatitis C in thalassemia major is evaluated, paying special attention to spontaneous viral clearance, to factors influencing the chronicity rate and fibrosis progression. Expand
Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa
In 45 sustained responders to interferon alfa and ribavirin, we found long-lasting elimination of hepatitis C virus RNA from serum and liver, together with histopathological improvement, suggestingExpand
Review article: genetic factors that modify the outcome of viral hepatitis
TLDR
Genetic factors can play an important role in treatment response and disease progression in chronic viral hepatitis and should be considered in the selection of patients for hepatitis B virus infection. Expand
Screening for Hepatitis C Virus Infection in Adults: A Systematic Review for the U.S. Preventive Services Task Force
TLDR
Although screening tests can accurately identify adults with chronic HCV infection, targeted screening strategies based on the presence of risk factors misses some patients withHCV infection. Expand
Therapy for hepatitis C--the costs of success.
TLDR
Three large, controlled trials of different regimens of oral antiviral agents for chronic hepatitis C, genotype 1, yielded rates of sustained virologic response of 93% to 99%. Expand
Management of hepatitis C.
TLDR
The management of special groups, including those with acute HCV infection, co-infected with hepatitis B (HBV) or human immunodeficiency virus (HIV), continues to be defined. Expand
Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement
  • V. Moyer
  • Medicine
  • Annals of Internal Medicine
  • 2013
TLDR
The Agency for Healthcare Research and Quality commissioned 2 systematic reviews on screening for and treatment of HCV infection in asymptomatic adults, focusing on evidence gaps identified in the previous USPSTF recommendation and new studies published since 2004. Expand
Birth cohort screening may help find hepatitis C cases.
TLDR
The ASCO authors called for further studies of palliative care to evaluate its optimaltiming,venue, and components; reimbursement models to facilitate its use; its application ofindiseases other thanlung cancer; and itffects the continuum of care, especially during the delivery of antitumor therapy. Expand
Ribavirin plus interferon versus interferon for chronic hepatitis C.
TLDR
Compared withinterferon alone, ribavirin plus interferon is more effective in clearing hepatitis C virus and improving liver histology, which may lead to reduced morbidity and mortality, however, combination therapy significantly increased the risk of several adverse events. Expand
...
1
2
3
4
5
...